In this study we have generated canine mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, from canine induced pluripotent stem cells (ciPSCs) by small-molecule inhibition of the transforming growth factor beta (TGFβ)/activin signaling pathway. These ciPSC-derived MSCs (ciPSC-MSCs) express the MSC markers CD73, CD90, CD105, STRO1, cPDGFRβ and cKDR, in addition to the pluripotency factors OCT4, NANOG and REX1. ciPSC-MSCs lack immunostaining for H3K27me3, suggesting that they possess two active X chromosomes. ciPSC-MSCs are highly proliferative and undergo robust differentiation along the osteo-, chondro- and adipogenic pathways, but do not form teratoma-like tissues in vitro. Of further significance for the translational potential of ciPSC-MSCs, we show that these cells can be encapsulated and maintained within injectable hydrogel matrices that, when functionalized with bound pentosan polysulfate, dramatically enhance chondrogenesis and inhibit osteogenesis. The ability to efficiently derive large numbers of highly proliferative canine MSCs from ciPSCs that can be incorporated into injectable, functionalized hydrogels that enhance their differentiation along a desired lineage constitutes an important milestone towards developing an effective MSC-based therapy for osteoarthritis in dogs, but equally provides a model system for assessing the efficacy and safety of analogous approaches for treating human degenerative joint diseases.
Get full access to this article
View all access options for this article.
References
1.
BarryF and MurphyM. (2013). Mesenchymal stem cells in joint disease and repair. Nat Rev Rheumatol, 9:584–594.
2.
In't AnkerPS, ScherjonSA, Kleijburg-van der KeurC, de Groot-SwingsGM, ClaasFH, FibbeWE and KanhaiHH. (2004). Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells, 22:1338–1345.
3.
YuM, XiaoZ, ShenL and LiL. (2004). Mid-trimester fetal blood-derived adherent cells share characteristics similar to mesenchymal stem cells but full-term umbilical cord blood does not. Br J Haematol, 124:666–675.
4.
TsaiMS, LeeJL, ChangYJ and HwangSM. (2004). Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum Reprod, 19:1450–1456.
5.
Al-AwqatiQ and OliverJA. (2002). Stem cells in the kidney. Kidney Int, 61:387–395.
6.
HuY, LiaoL, WangQ, MaL, MaG, JiangX and ZhaoRC. (2003). Isolation and identification of mesenchymal stem cells from human fetal pancreas. J Lab Clin Med, 141:342–349.
7.
CampagnoliC, RobertsIA, KumarS, BennettPR, BellantuonoI and FiskNM. (2001). Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood, 98:2396–2402.
8.
In't AnkerPS, NoortWA, ScherjonSA, Kleijburg-van der KeurC, KruisselbrinkAB, van BezooijenRL, BeekhuizenW, WillemzeR, KanhaiHH and FibbeWE. (2003). Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica, 88:845–852.
9.
GotherstromC, WestA, LidenJ, UzunelM, LahesmaaR and Le BlancK. (2005). Difference in gene expression between human fetal liver and adult bone marrow mesenchymal stem cells. Haematologica, 90:1017–1026.
10.
KernS, EichlerH, StoeveJ, KlüterH and BiebackK. (2006). Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells, 24:1294–1301.
11.
GuillotPV, GotherstromC, ChanJ, KurataH and FiskNM. (2007). Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells, 25:646–654.
12.
BiebackK, KernS, KocaomerA, FerlikK and BugertP. (2008). Comparing mesenchymal stromal cells from different human tissues: bone marrow, adipose tissue and umbilical cord blood. Biomed Mater Eng, 18:S71–S76.
13.
StolzingA, JonesE, McGonagleD and ScuttA. (2008). Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev, 129:163–173.
14.
ZhouS, GreenbergerJS, EpperlyMW, GoffJP, AdlerC, LeboffMS and GlowackiJ. (2008). Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell, 7:335–343.
15.
ChenYS, PelekanosRA, EllisRL, HorneR, WolvetangEL and FiskNM. (2012). Small molecule mesengenic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells. Stem Cells Transl Med, 1:83–95.
16.
SmithGK, MayhewPD, KapatkinAS, McKelviePJ, ShoferFS and GregorTP. (2001). Evaluation of risk factors for degenerative joint disease associated with hip dysplasia in German Shepherd Dogs, Golden Retrievers, Labrador Retrievers, and Rottweilers. J Am Vet Med Assoc, 219:1719–1724.
17.
ShankarH, ScarlettJA and AbramSE. (2009). Anatomy and pathophysiology of intervertebral disc disease. Tech Regional Anes Pain Man, 13:67–75.
18.
BrissonBA. (2010). Intervertebral disc disease in dogs. Vet Clin Small Anim, 40:829–858.
19.
NeupaneM, ChangCC, KiupelM and Yuzbasiyan-GurkanV. (2008). Isolation and characterization of canine adipose-derived mesenchymal stem cells. Tissue Eng Part A, 14:1007–1015.
20.
VieiraNM, BrandaliseV, ZucconiE, SeccoM, StraussBE and ZatzM. (2010). Isolation, characterization, and differentiation potential of canine adipose-derived stem cells. Cell Transplant, 19:279–289.
21.
KisielAH, McDuffeeLA, MasaoudE, BaileyTR, Esparza GonzalezBP and Nino-FongR. (2012). Isolation, characterization, and in vitro proliferation of canine mesenchymal stem cells derived from bone marrow, adipose tissue, muscle, and periosteum. Am J Vet Res, 73:1305–1317.
22.
ReichCM, RaabeO, WenischS, BridgerPS, KramerM and ArnholdS. (2012). Isolation, culture and chondrogenic differentiation of canine adipose tissue- and bone marrow-derived mesenchymal stem cells—a comparative study. Vet Res Commun, 36:139–148.
23.
TakemitsuH, ZhaoD, YamamotoI, HaradaY, MichishitaM and AraiT. (2012). Comparison of bone marrow and adipose tissue-derived canine mesenchymal stem cells. BMC Vet Res, 8:150.
24.
ZhangN, DietrichMA and LopezMJ. (2013). Canine intra-articular multipotent stromal cells (MSC) from adipose tissue have the highest in vitro expansion rates, multipotentiality, and MSC immunophenotypes. Vet Surg, 42:137–146.
25.
GuercioA, Di BellaS, CasellaS, Di MarcoP, RussoC and PiccioneG. (2013). Canine mesenchymal stem cells (MSCs): characterization in relation to donor age and adipose tissue-harvesting site. Cell Biol Int, 37:789–798.
26.
WhitworthDJ, OvchinnikovDA and WolvetangEJ. (2012). Generation and characterization of LIF-dependent canine induced pluripotent stem cells from adult dermal fibroblasts. Stem Cells Dev, 21:2288–2297.
27.
FrithJE, CameronAR, MenziesDJ, GhoshP, WhiteheadDL, GronthosS, ZannettinoAC and Cooper-WhiteJJ. (2013). An injectable hydrogel incorporating mesenchymal precursor cells and pentosan polysulphate for intervertebral disc regeneration. Biomaterials, 34:9430–9440.
28.
SoleimaniM and NadriS. (2009). A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. Nat Protoc, 4:102–106.
29.
BarlowS, BrookeG, ChatterjeeK, PriceG, PelekanosR, RossettiT, DoodyM, VenterD, PainS, GilshenanK and AtkinsonK. (2008). Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev, 17:1095–1107.
30.
PayerB, LeeJT and NamekawaSH. (2011). X-inactivation and X-reactivation: epigenetic hallmarks of mammalian reproduction and pluripotent stem cells. Hum Genet, 130:265–280.
31.
WhitworthDJ, OvchinnikovDA, SunJ, FortunaPRJ and WolvetangEJ. (2014). Generation and characterization of leukemia inhibitory factor-dependent equine induced pluripotent stem cells from adult dermal fibroblasts. Stem Cells Dev, 23:1515–1523.
32.
FrithJE, MenziesDJ, CameronAR, GhoshP, WhiteheadDL, GronthosS, ZannettinoAC and Cooper-WhiteJJ. (2014). Effects of bound versus soluble pentosan polysulphate in PEG/HA-based hydrogels tailored for intervertebral disc regeneration. Biomaterials, 35:1150–1162.
33.
BurdickJA and AnsethKS. (2002). Photoencapsulation of osteoblasts in injectable RGD-modified PEG hydrogels for bone tissue engineering. Biomaterials, 23:4315–4323.
34.
GhoshP, WuJ, ShimmonS, ZannettinoAC, GronthosS and ItescuS. (2010). Pentosan polysulfate promotes proliferation and chondrogenic differentiation of adult human bone marrow-derived mesenchymal precursor cells. Arthritis Res Ther, 12:R28.
35.
CsakiC, MatisU, MobasheriA, YeH and ShakibaeiM. (2007). Chondrogenesis, osteogenesis and adipogenesis of canine mesenchymal stem cells: a biochemical, morphological and ultrastructural study. Histochem Cell Biol, 128:507–520.
36.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopDJ and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
37.
CalloniR, CorderoEA, HenriquesJA and BonattoD. (2013). Reviewing and updating the major molecular markers for stem cells. Stem Cells Dev, 22:1455–1476.
38.
BhandariDR, SeoKW, RohKH, JungJW, KangSK and KangKS. (2010). REX-1 expression and p38 MAPK activation status can determine proliferation/differentiation fates in human mesenchymal stem cells. PLoS One, 5:e10493.
39.
BaisMV, ShabinZM, YoungM, EinhornTA, KottonDN and GerstnefeldLC. (2012). Role of Nanog in the maintenance of marrow stromal stem cells during post natal bone regeneration. Biochem Biophys Res Commun, 417:211–216.
40.
GontanC, AchameEM, DemmersJ, BarakatTS, RentmeesterE, van IJckenW, GrootegoedJA and GribnauJ. (2012). RNF12 initiates X-chromosome inactivation by targeting REX1 for degradation. Nature, 485:386–390.
41.
DiMarinoAM, CaplanAI and BonfieldTL. (2013). Mesenchymal stem cells in tissue repair. Front Immunol, 4:201.
42.
McCoyRJ, WidaaA, WattersKM, WuerstleM, StallingsRL, DuffyGP and O'BrienFJ. (2013). Orchestrating osteogenic differentiation of mesenchymal stem cells-identification of placental growth factor as a mechanosensitive gene with a pro-osteogenic role. Stem Cells, 31:2420–2431.
43.
McBeathR, PironeDM, NelsonCM, BhadrirajuK and ChenCS. (2004). Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev Cell, 6:483–495.
DalbyMJ, GadegaardN, TareR, AndarA, RiehleMO, HerzykP, WilkinsonCD and OreffoRO. (2007). The control of human mesenchymal cell differentiation using nanoscale symmetry and disorder. Nat Mater, 6:997–1003.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
